Bioventus Inc.
NASDAQ:BVSMedical - Devices
+$0.18 today
- Market cap
- $727.20M
- Beta
- 0.67
- P/E (TTM)
- 20.6
- EPS (TTM)
- $0.42
Volume 0.70M
Average 0.56M
BVS Total Debt
Short-term and long-term borrowings combined.
Bioventus Inc.NASDAQ: BVS
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt falls 21.3% from a year ago
Total debt stood at $272.08M at the end of Q1 FY2026, down 21.3% from a year earlier and down 12.6% from the prior quarter. Over 3 fiscal years it compounded at -9.4% a year.
Context
- Total debt amounted to 41.8% of total assets at the end of Q1 FY2026, down 8.2 pp from a year earlier.
- Total debt increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -21.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 311.35M USD
- Year-over-year change
- -7.2%
- 4-year CAGR
- -3.4%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 311.35M | -7.2% |
| FY2024 | 2024-12-31 | 335.63M | -15.0% |
| FY2023 | 2023-12-31 | 394.85M | -5.6% |
| FY2022 | 2022-12-31 | 418.07M | +16.9% |
| FY2021 | 2021-12-31 | 357.68M | — |
Total Debt vs competitors
How BVS compares with its peers on the latest reported figures
- BVS's Mar 2026 total debt of $272.08M is the 3rd highest of the 9 companies compared; the peer median is $63.74M.
- Its year-over-year change of -21.3% is the 8th highest of 9, against a peer median of +1.1%.
- Total debt amounts to 41.8% of total assets for BVS, versus a peer median of 23.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $3.33B | +0.2% | +5.0% | 31.8% | |
| Mar 2026 | $2.04B | +1.0% | +7.6% | 57.0% | |
| Mar 2026 | $272.08M | -21.3% | -9.4% | 41.8% | |
| Mar 2026 | $234.39M | +21.6% | +120.0% | 26.4% | |
| Mar 2026 | $70.86M | +66.2% | +2.4% | 13.6% | |
| Jun 2026 | $56.61M | +35.1% | +10.3% | 94.8% | |
| Mar 2026 | $25.74M | +1.2% | -5.3% | 14.3% | |
| Mar 2026 | $17.59M | -5.7% | -24.6% | 5.7% | |
| Mar 2026 | $15.44M | -55.0% | +18.9% | 19.8% | |
| Peer median (excluding BVS) | $63.74M | +1.1% | +6.3% | 23.1% | |
Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 43.93M | 30.19M | 36.96M | 41.58M | 51.24M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 124.96M | 136.3M | 122.79M | 127.39M | 128.3M |
| Inventory | 61.69M | 84.77M | 91.33M | 92.48M | 82.24M |
| Other Current Assets | 20.28M | 16.89M | 16.91M | 14.16M | 11.07M |
| Total Current Assets | 263.1M | 272.58M | 268M | 275.61M | 272.84M |
| Property, Plant & Equipment (Net) | 40.17M | 44.15M | 49.96M | 33.52M | 27.02M |
| Goodwill | 147.62M | 7.46M | 7.46M | 7.46M | 7.46M |
| Intangible Assets | 695.19M | 639.85M | 482.35M | 404.73M | 368.42M |
| Long-term Investments | 29.29M | 2.64M | 0 | 0 | 0 |
| Tax Assets | 481K | 0 | 0 | 4.75M | 5.52M |
| Other Non-current Assets | 50M | 405.98M | 3.14M | 1.89M | 2.29M |
| Total Non-current Assets | 962.76M | 1.1B | 542.91M | 452.35M | 410.72M |
| Total Assets | 1.23B | 1.37B | 810.91M | 727.96M | 683.56M |
| Account Payables | 16.92M | 36.7M | 23.04M | 23.69M | 10.93M |
| Short-term Debt | 18.04M | 33.06M | 27.85M | 27.34M | 19.21M |
| Tax Payables | 8.14M | 2.57M | 4.75M | 3.87M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 46.48M | 151.07M | 34.23M | 51.13M | 93.51M |
| Total Current Liabilities | 180.86M | 304.02M | 175.5M | 210.4M | 160.38M |
| Long-term Debt | 339.64M | 385.01M | 367M | 308.29M | 278.95M |
| Deferred Tax Liabilities | 133.52M | 2.25M | 1.21M | 564K | 433K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 38.05M | 269.15M | 46.08M | 23.1M | 2.16M |
| Total Non-current Liabilities | 511.21M | 656.41M | 414.3M | 331.95M | 294.73M |
| Total Liabilities | 692.07M | 960.43M | 589.79M | 542.35M | 455.11M |
| Common Stock | 75K | 78K | 79K | 82K | 83K |
| Retained Earnings | (6.6M) | (165.31M) | (321.54M) | (355.08M) | (334.93M) |
| Accumulated OCI | 179K | (110K) | 794K | (2.57M) | (1.9M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 74.87M | 86.98M | 47.53M | 37.66M | 44.34M |
| Total Equity | 533.79M | 412.22M | 221.12M | 185.6M | 228.45M |
| Total Debt | 357.68M | 418.07M | 394.85M | 335.63M | 311.35M |
| Net Debt | 313.75M | 387.88M | 357.88M | 294.05M | 260.11M |
Bioventus Inc.
NASDAQ:BVS
Intrinsic Alpha fair value
Locked
Current Price
$10.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.